Storia in 2 fonti

The FDA is moving faster on psychedelics. Washington must do more

In response to Trump's recent executive order, the FDA announced plans to expedite the review of certain psychedelic medicines for mental health conditions.

Raccontata da

scientificamerican.com

washingtonexaminer.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

washingtonexaminer.comStai leggendo1 mesi fa

The FDA is moving faster on psychedelics. Washington must do more

In response to Trump's recent executive order, the FDA announced plans to expedite the review of certain psychedelic medicines for mental health conditions.

originale

scientificamerican.com1 mesi fa

Trump's psychedelics executive order could accelerate new treatments—including for children

Trump accelerates psychedelic research; FDA evaluates psilocybin for depression, trials on minors inevitable. Regulatory opening creates biotech opportunity but poses ethical risks (developing brain, informed consent): governance and reputational hazards critical.

Leggi questa versione →

Timeline cronologica

lunedì 1 giugno 2026·scientificamerican.com
Trump's psychedelics executive order could accelerate new treatments—including for children
The Trump administration has fast-tracked research into psychedelics, and experts say it is likely a matter of time before the drugs are used to treat minors
mercoledì 3 giugno 2026·washingtonexaminer.com
The FDA is moving faster on psychedelics. Washington must do more
In response to Trump's recent executive order, the FDA announced plans to expedite the review of certain psychedelic medicines for mental health conditions.